Lisa Ng

List of Publications by Year
in descending order

161 papers	13,357 citations	36303 51 h-index	26613 107 g-index
175 all docs	175 docs citations	175 times ranked	23277 citing authors

#	Article	IF	Citations
1	Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Î”382 Variant Infection. Journal of Clinical Immunology, 2022, 42, 214-229.	3.8	15
2	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	6.9	31
3	Malaria abrogates Oâ€™nyongâ€“nyong virus pathologies by restricting virus infection in nonimmune cells. Life Science Alliance, 2022, 5, e202101272.	2.8	5
4	Discrepant serological findings in SARSâ€CoVâ€2 PCRâ€negative hospitalized patients with fever and acute respiratory symptoms during the pandemic. Journal of Medical Virology, 2022, , .	5.0	1
5	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 2088-2096.	5.8	23
6	Organâ€specific immune response in lethal SARSâ€CoVâ€2 infection by deep spatial phenotyping. Clinical and Translational Immunology, 2022, 11, .	3.8	0
7	Rapid microfluidic platform for screening and enrichment of cells secreting virus neutralizing antibodies. Lab on A Chip, 2022, 22, 2578-2589.	6.0	4
8	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Journal of Experimental Medicine, 2022, 219, .	8.5	59
9	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	5.8	143
10	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64.	9.6	444
11	Human neutralising antibodies elicited by SARSâ€CoVâ€2 nonâ€D614G variants offer crossâ€protection against the SARSâ€CoVâ€2 D614G variant. Clinical and Translational Immunology, 2021, 10, e1241.	3.8	18
12	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Reports Medicine, 2021, 2, 100193.	6.5	37
13	COVID-19 vaccines and kidney disease. Nature Reviews Nephrology, 2021, 17, 291-293.	9.6	91
14	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 2021, 10, .	6.0	113
15	Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape. Microorganisms, 2021, 9, 899.	3.6	8
16	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine, 2021, 66, 103319.	6.1	21
17	Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofab156.	0.9	77
18	Asymptomatic COVIDâ€19: disease tolerance with efficient antiâ€viral immunity against SARSâ€CoVâ€2. EMBO Molecular Medicine, 2021, 13, e14045.	6.9	36

#	Article	IF	Citations
19	Epitope-Functionalized Gold Nanoparticles for Rapid and Selective Detection of SARS-CoV-2 IgG Antibodies. ACS Nano, 2021, 15, 12286-12297.	14.6	73
20	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	7.3	322
21	Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells. Nature Microbiology, 2021, 6, 991-999.	13.3	26
22	Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific, 2021, 15, 100276.	2.9	22
23	Gas6 drives Zika virus-induced neurological complications in humans and congenital syndrome in immunocompetent mice. Brain, Behavior, and Immunity, 2021, 97, 260-274.	4.1	10
24	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. Npj Vaccines, 2021, 6, 125.	6.0	17
25	A promiscuous interaction of SARS-CoV-2 with bacterial products. Journal of Molecular Cell Biology, 2021, 12, 914-915.	3.3	1
26	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. Frontiers in Immunology, 2021, 12, 710217.	4.8	8
27	Pathogenic Th1 responses in CHIKVâ€induced inflammation and their modulation upon Plasmodium parasites coâ€infection. Immunological Reviews, 2020, 294, 80-91.	6.0	9
28	Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nature Communications, 2020, 11, 5243.	12.8	138
29	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	6.1	120
30	Safety and potential efficacy of cyclooxygenaseâ€2 inhibitors in coronavirus disease 2019. Clinical and Translational Immunology, 2020, 9, e1159.	3.8	19
31	Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARSâ€CoVâ€2) infection. Clinical and Translational Immunology, 2020, 9, e1160.	3.8	31
32	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. Viruses, 2020, 12, 1164.	3.3	51
33	Systematic analysis of diseaseâ€specific immunological signatures in patients with febrile illness from Saudi Arabia. Clinical and Translational Immunology, 2020, 9, e1163.	3.8	20
34	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa375.	0.9	33
35	Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet, The, 2020, 396, 603-611.	13.7	394
36	Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nature Communications, 2020, 11, 2806.	12.8	362

#	Article	IF	Citations
37	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell, 2020, 181, 1194-1199.	28.9	185
38	Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus Infection. Frontiers in Immunology, 2020, 11, 894.	4.8	5
39	TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection. Scientific Reports, 2020, 10, 3810.	3.3	11
40	Role of T Cells in Chikungunya Virus Infection and Utilizing Their Potential in Anti-Viral Immunity. Frontiers in Immunology, 2020, 11, 287.	4.8	12
41	The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 2020, 20, 363-374.	22.7	3,347
42	Type I interferon shapes the quantity and quality of the antiâ€Zika virus antibody response. Clinical and Translational Immunology, 2020, 9, e1126.	3.8	8
43	Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Frontiers in Immunology, 2020, 11, 879.	4.8	218
44	Novel differential linear Bâ€cell epitopes to identify Zika and dengue virus infections in patients. Clinical and Translational Immunology, 2019, 8, e1066.	3.8	32
45	Immunological observations and transcriptomic analysis of trimesterâ€specific fullâ€term placentas from three Zika virusâ€infected women. Clinical and Translational Immunology, 2019, 8, e01082.	3.8	20
46	Investigating the Cellular Transcriptomic Response Induced by the Makona Variant of Ebola Virus in Differentiated THP-1 Cells. Viruses, 2019, 11, 1023.	3.3	6
47	VCP/p97 Is a Proviral Host Factor for Replication of Chikungunya Virus and Other Alphaviruses. Frontiers in Microbiology, 2019, 10, 2236.	3.5	14
48	Chikungunya virus drug discovery: still a long way to go?. Expert Opinion on Drug Discovery, 2019, 14, 855-866.	5.0	21
49	Mutating chikungunya virus nonâ€structural protein produces potent liveâ€attenuated vaccine candidate. EMBO Molecular Medicine, 2019, 11, .	6.9	23
50	ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. Journal of Infectious Diseases, 2019, 220, 203-212.	4.0	11
51	Understanding Molecular Pathogenesis with Chikungunya Virus Research Tools. Current Topics in Microbiology and Immunology, 2019, , 1.	1.1	6
52	Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients. , 2019, 8, e1066.		1
53	Viperin controls chikungunya virusâ€“specific pathogenic T cell IFNÎ³ Th1 stimulation in mice. Life Science Alliance, 2019, 2, e201900298.	2.8	31
54	Efficient detection of Zika virus RNA in patientsâ€™ blood from the 2016 outbreak in Campinas, Brazil. Scientific Reports, 2018, 8, 4012.	3.3	19

#	Article	IF	Citations
55	Longitudinal Study of Cellular and Systemic Cytokine Signatures to Define the Dynamics of a Balanced Immune Environment During Disease Manifestation in Zika Virusâ€“Infected Patients. Journal of Infectious Diseases, 2018, 218, 814-824.	4.0	40
56	Mosquito Saliva Reshapes Alphavirus Infection and Immunopathogenesis. Journal of Virology, 2018, 92, .	3.4	21
57	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. ACS Infectious Diseases, 2018, 4, 605-619.	3.8	18
58	Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. Scientific Reports, 2018, 8, 1860.	3.3	38
59	Interferon regulatory factor 1 is essential for pathogenic CD8+ T cell migration and retention in the brain during experimental cerebral malaria. Cellular Microbiology, 2018, 20, e12819.	2.1	12
60	Zika Virus Infection Preferentially Counterbalances Human Peripheral Monocyte and/or NK Cell Activity. MSphere, 2018, 3, .	2.9	32
61	Zika virus: from an obscurity to a priority. Microbes and Infection, 2018, 20, 635-645.	1.9	25
62	Zika Virus and the Eye. Ocular Immunology and Inflammation, 2018, 26, 654-659.	1.8	32
63	Coâ€infection with Chikungunya virus alters trafficking of pathogenic <scp>CD</scp> 8 ⁺ T cells into the brain and prevents Plasmodium â€induced neuropathology. EMBO Molecular Medicine, 2018, 10, 121-138.	6.9	21
64	Fast Tracks and Roadblocks for Zika Vaccines. Vaccines, 2018, 6, 77.	4.4	7
65	Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. Scientific Reports, 2018, 8, 17125.	3.3	4
66	Plasmodium co-infection protects against chikungunya virus-induced pathologies. Nature Communications, 2018, 9, 3905.	12.8	23
67	Therapeutic modulation of the bile acid pool byCyp8b1knockdown protects against nonalcoholic fatty liver disease in mice. FASEB Journal, 2018, 32, 3792-3802.	0.5	37
68	The 2016 Singapore Zika virus outbreak did not cause a surge in Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2018, 23, 197-201.	3.1	10
69	Nonstructural Proteins of Alphavirusâ€”Potential Targets for Drug Development. Viruses, 2018, 10, 71.	3.3	47
70	Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. Viruses, 2018, 10, 268.	3.3	126
71	Viperin Poisons Viral Replication. Cell Host and Microbe, 2018, 24, 181-183.	11.0	7
72	Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infectious Diseases, The, 2017, 17, e107-e117.	9.1	302

#	Article	IF	Citations
73	Fingolimod treatment abrogates chikungunya virusâ€“induced arthralgia. Science Translational Medicine, 2017, 9, .	12.4	57
74	Chikungunya virus nsP4 RNA-dependent RNA polymerase core domain displays detergent-sensitive primer extension and terminal adenylyltransferase activities. Antiviral Research, 2017, 143, 38-47.	4.1	39
75	Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Research, 2017, 144, 223-246.	4.1	104
76	A Sensitive Method for Detecting Zika Virus Antigen in Patientsâ€™ Whole-Blood Specimens as an Alternative Diagnostic Approach. Journal of Infectious Diseases, 2017, 216, 182-190.	4.0	25
77	Zika Virus Infects Human Fetal Brain Microglia and Induces Inflammation. Clinical Infectious Diseases, 2017, 64, 914-920.	5.8	133
78	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus. Journal of Medicinal Chemistry, 2017, 60, 3165-3186.	6.4	30
79	Clinical features of patients with Zika and dengue virus co-infection in Singapore. Journal of Infection, 2017, 74, 611-615.	3.3	24
80	Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. Antiviral Research, 2017, 139, 79-87.	4.1	20
81	Persistence of Zika virus in conjunctival fluid of convalescence patients. Scientific Reports, 2017, 7, 11194.	3.3	43
82	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nature Microbiology, 2017, 2, 1435-1445.	13.3	77
83	A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses. Journal of Antimicrobial Chemotherapy, 2017, 72, 2973-2989.	3.0	18
84	Age has a role in driving host immunopathological response to alphavirus infection. Immunology, 2017, 152, 545-555.	4.4	10
85	Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virusâ€“Infected Patients in Brazil. Journal of Infectious Diseases, 2017, 216, 172-181.	4.0	82
86	Immunopathology of Chikungunya Virus Infection: Lessons Learned from Patients and Animal Models. Annual Review of Virology, 2017, 4, 413-427.	6.7	33
87	Severity of Plasma Leakage Is Associated With High Levels of Interferon Î³â€“Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection. Journal of Infectious Diseases, 2017, 215, 42-51.	4.0	51
88	Immunopathogenesis and Virusâ€“Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease. Frontiers in Microbiology, 2017, 8, 2249.	3.5	60
89	Seroprevalence of antibodies against chikungunya virus in Singapore resident adult population. PLoS Neglected Tropical Diseases, 2017, 11, e0006163.	3.0	25
90	Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight, 2017, 2, .	5.0	74

#	Article	IF	Citations
91	Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice. Scientific Reports, 2016, 6, 37603.	3.3	11
92	The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. Journal of Virology, 2016, 90, 9743-9757.	3.4	127
93	Early clearance of Chikungunya virus in children is associated with a strong innate immune response. Scientific Reports, 2016, 6, 26097.	3.3	30
94	Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. Journal of Virology, 2016, 90, 1169-1177.	3.4	23
95	Host Response and Mechanisms of Subversion of Chikungunya. , 2016, , 19-32.		0
96	Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virusâ€specific neutralizing antibody response. EMBO Molecular Medicine, 2015, 7, 24-41.	6.9	81
97	Limitations of Current in Vivo Mouse Models for the Study of Chikungunya Virus Pathogenesis. Medical Sciences (Basel, Switzerland), 2015, 3, 64-77.	2.9	12
98	Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells. PLoS Pathogens, 2015, 11, e1005191.	4.7	18
99	A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. Journal of Virological Methods, 2015, 222, 55-61.	2.1	10
100	Expanding Regulatory T Cells Alleviates Chikungunya Virus-Induced Pathology in Mice. Journal of Virology, 2015, 89, 7893-7904.	3.4	49
101	A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection. Journal of Infectious Diseases, 2015, 211, 1925-1935.	4.0	95
102	Role of Pentraxin 3 in Shaping Arthritogenic Alphaviral Disease: From Enhanced Viral Replication to Immunomodulation. PLoS Pathogens, 2015, 11, e1004649.	4.7	32
103	Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral Research, 2015, 120, 165-174.	4.1	52
104	Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients. PLoS Neglected Tropical Diseases, 2015, 9, e3445.	3.0	60
105	Therapeutics and Vaccines Against Chikungunya Virus. Vector-Borne and Zoonotic Diseases, 2015, 15, 250-257.	1.5	58
106	Chikungunya Virus Pathogenesis and Immunity. Vector-Borne and Zoonotic Diseases, 2015, 15, 241-249.	1.5	59
107	Chikungunya: International Focus Issue. Vector-Borne and Zoonotic Diseases, 2015, 15, 221-222.	1.5	4
108	Caribbean and La RÃ©union Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology. Journal of Virology, 2015, 89, 7955-7969.	3.4	95

#	Article	IF	Citations
109	Major advances against a moving target of CNS infections. Nature Reviews Neurology, 2015, 11, 623-624.	10.1	3
110	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses. Journal of Medicinal Chemistry, 2015, 58, 9196-9213.	6.4	40
111	Clustering HLA Class I Superfamilies Using Structural Interaction Patterns. PLoS ONE, 2014, 9, e86655.	2.5	21
112	Arbovirus Infections. , 2014, , 129-161.e3.		9
113	An Integrated Lab-on-Chip for Rapid Identification and Simultaneous Differentiation of Tropical Pathogens. PLoS Neglected Tropical Diseases, 2014, 8, e3043.	3.0	33
114	Prime-Boost Immunization Strategies against Chikungunya Virus. Journal of Virology, 2014, 88, 13333-13343.	3.4	63
115	The fine line between protection and pathology in neurotropic flavivirus and alphavirus infections. Future Virology, 2014, 9, 313-330.	1.8	5
116	Unique Epitopes Recognized by Antibodies Induced in Chikungunya Virus-Infected Non-Human Primates: Implications for the Study of Immunopathology and Vaccine Development. PLoS ONE, 2014, 9, e95647.	2.5	44
117	Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. Virology Journal, 2013, 10, 169.	3.4	37
118	An Essential Role of Antibodies in the Control of Chikungunya Virus Infection. Journal of Immunology, 2013, 190, 6295-6302.	0.8	135
119	Neutrophils: Neglected Players in Viral Diseases. DNA and Cell Biology, 2013, 32, 665-675.	1.9	21
120	Macrophage Migration Inhibitory Factor Receptor CD74 Mediates Alphavirusâ€Induced Arthritis and Myositis in Murine Models of Alphavirus Infection. Arthritis and Rheumatism, 2013, 65, 2724-2736.	6.7	40
121	A Pathogenic Role for CD4+ T Cells during Chikungunya Virus Infection in Mice. Journal of Immunology, 2013, 190, 259-269.	0.8	196
122	Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection. Journal of Infectious Diseases, 2012, 205, 1147-1154.	4.0	156
123	Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development. Journal of Virology, 2012, 86, 13005-13015.	3.4	125
124	Cerebral malaria. Virulence, 2012, 3, 193-201.	4.4	118
125	Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Molecular Medicine, 2012, 4, 330-343.	6.9	177
126	Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology. Immunologic Research, 2012, 53, 136-147.	2.9	37

#	Article	IF	Citations
127	Viperin restricts chikungunya virus replication and pathology. Journal of Clinical Investigation, 2012, 122, 4447-4460.	8.2	163
128	Host response to Chikungunya virus and perspectives for immune-based therapies. Future Virology, 2011, 6, 975-984.	1.8	13
129	Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency. Journal of Immunology, 2011, 186, 3258-3264.	0.8	81
130	Understanding infectious agents from an in silico perspective. Drug Discovery Today, 2011, 16, 42-49.	6.4	3
131	In silico prediction of the granzyme B degradome. BMC Genomics, 2011, 12, S11.	2.8	7
132	Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants. PLoS Pathogens, 2011, 7, e1002390.	4.7	88
133	Persistent Arthralgia Induced by Chikungunya Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage Colony-Stimulating Factor. Journal of Infectious Diseases, 2011, 203, 149-157.	4.0	305
134	SVM-based prediction of linear B-cell epitopes using Bayes Feature Extraction. BMC Genomics, 2010, 11, S21.	2.8	68
135	HLA Class I Restriction as a Possible Driving Force for Chikungunya Evolution. PLoS ONE, 2010, 5, e9291.	2.5	15
136	Re-emergence of Chikungunya virus in South-east Asia: virological evidence from Sri Lanka and Singapore. Journal of General Virology, 2010, 91, 1067-1076.	2.9	124
137	Active Infection of Human Blood Monocytes by Chikungunya Virus Triggers an Innate Immune Response. Journal of Immunology, 2010, 184, 5903-5913.	0.8	237
138	Rapid detection of viral RNA by a pocket-size real-time PCR system. Lab on A Chip, 2010, 10, 2632.	6.0	31
139	IL-1Î², IL-6, and RANTES as Biomarkers of Chikungunya Severity. PLoS ONE, 2009, 4, e4261.	2.5	249
140	Cleavage of the SARS Coronavirus Spike Glycoprotein by Airway Proteases Enhances Virus Entry into Human Bronchial Epithelial Cells In Vitro. PLoS ONE, 2009, 4, e7870.	2.5	142
141	Chikungunya fever â€“ Re-emergence of an old disease. Microbes and Infection, 2009, 11, 1163-1164.	1.9	19
142	Immuno-biology of Chikungunya and implications for disease intervention. Microbes and Infection, 2009, 11, 1186-1196.	1.9	73
143	Chikungunya: a bending reality. Microbes and Infection, 2009, 11, 1165-1176.	1.9	93
144	Cellular transcription modulator SMARCE1 binds to HBV core promoter containing naturally occurring deletions and represses viral replication. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 1075-1084.	3.8	9

#	Article	IF	Citations
145	Catching bird flu in a droplet. Nature Medicine, 2007, 13, 1259-1263.	30.7	195
146	Specific detection of H5N1 avian influenza A virus in field specimens by a one-step RT-PCR assay. BMC Infectious Diseases, 2006, 6, 40.	2.9	32
147	A cell-based system for hepatitis B virus replication: significance of clinically enhanced viral replication in relation to deletions in viral core promoter. Frontiers in Bioscience - Landmark, 2005, 10, 2001.	3.0	7
148	Host Heterogeneous Ribonucleoprotein K (hnRNP K) as a Potential Target to Suppress Hepatitis B Virus Replication. PLoS Medicine, 2005, 2, e163.	8.4	47
149	SARS Transmission Pattern in Singapore Reassessed by Viral Sequence Variation Analysis. PLoS Medicine, 2005, 2, e43.	8.4	37
150	Detection of Severe Acute Respiratory Syndrome Coronavirus in Blood of Infected Patients. Journal of Clinical Microbiology, 2004, 42, 347-350.	3.9	51
151	A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infectious Diseases, 2004, 4, 34.	2.9	77
152	Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet, The, 2003, 361, 1779-1785.	13.7	423
153	The Virus That Changed My World. PLoS Biology, 2003, 1, e66.	5.6	2
154	Membrane Association and Dimerization of a Cysteine-Rich, 16-Kilodalton Polypeptide Released from the C-Terminal Region of the Coronavirus Infectious Bronchitis Virus 1a Polyprotein. Journal of Virology, 2002, 76, 6257-6267.	3.4	27
155	Further Identification and Characterization of Products Processed from the Coronavirus Avian Infectious Bronchitis Virus (IBV) 1a Polyprotein by the 3C-like Proteinase. Advances in Experimental Medicine and Biology, 2001, 494, 291-298.	1.6	6
156	Further Characterization of the Coronavirus Infectious Bronchitis Virus 3C-like Proteinase and Determination of a New Cleavage Site. Virology, 2000, 272, 27-39.	2.4	42
157	Identification of a Novel Cleavage Activity of the First Papain-Like Proteinase Domain Encoded by Open Reading Frame 1a of the Coronavirus Avian Infectious Bronchitis Virus and Characterization of the Cleavage Products. Journal of Virology, 2000, 74, 1674-1685.	3.4	91
158	Identification of a 24-kDa Polypeptide Processed from the Coronavirus Infectious Bronchitis Virus 1a Polyprotein by the 3C-like Proteinase and Determination of Its Cleavage Sites. Virology, 1998, 243, 388-395.	2.4	37
159	Further Characterisation of the Coronavirus IBV ORF 1a Products Encoded by the 3C-Like Proteinase Domain and the Flanking Regions. Advances in Experimental Medicine and Biology, 1998, 440, 161-171.	1.6	2
160	Type I Interferon Shapes the Quantity and Quality of the Anti-Zika Virus Antibody Response. SSRN Electronic Journal, 0, , .	0.4	0
161	Association of SARS-CoV-2 Clades with Clinical, Inflammatory and Virologic Outcomes: An Observational Study. SSRN Electronic Journal, 0, , .	0.4	0